Psychiatria Danubina, Vol. 21 No. 3, 2009.
Izlaganje sa skupa
PSYCHOFARMACOLOGY IN THE PREVENTION OF SOMATIC COMORBID DISEASES IN MENTALLY ILL PATIENTS
Vlado Jukić
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Zrinka Petrović
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Petrana Brečić
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Aida Križaj
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Aleksandar Savić
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Ana Bačeković
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Petar Bilić
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Jelena Sušac
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Antonija Mandić
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Ivana Pražen
; University Department of Psychiatry, Psychiatric Hospital Vrapče, Zagreb, Croatia
Sažetak
It is a well known fact that mentally ill patients, especially those with schizophrenia, have a higher incidence of somatic diseases than the general population and finally a significantly shorter life expectancy. In this paper a comparison is made between schizophrenia and somatic comorbidity before the era of antipsychotics and after, with consideration to the prevalent morbidity during each of these periods. In the period before antipsychotics acute infectious diseases and TBC were the prevalent comorbid diseases. High comorbidity rates were due not only to epidemics but also poor treatment success, deficient health habits and poor personal hygiene. In the period after the discovery of antipsychotics significant changes in morbidity occurred with the prevalence of chronic degenerative diseases, primarily diabetes, hypertension and dyslipidemia. Studies show that new generation antipsychotics partly generate the occurrence of metabolic disorders, which makes it necessary to consider the choice of antipsychotic depending on the
assessed risk in every individual case.
Ključne riječi
schizophrenia - somatic comorbiditiy - antipsychotics
Hrčak ID:
49223
URI
Datum izdavanja:
25.6.2009.
Posjeta: 1.040 *